Story: 

Premise Biosystems is developing an automated cancer testing machine that precisely extracts circulating tumor cells (CTC) from blood sample. Liquid biopsy negative selection helps increase precision so that doctors can detect early stage cancer in time.

Project Image: 
Project Owner: 
Premise Biosystems
Project Category: 
Project Status: 
Project Target: 
12000000.00
Project Stock: 
20.00
Project Support Count: 
6
Project Money: 
6000000.00
Project Order: 
1